Adriana Kahn, Assistant Professor at Yale University, shared a post on X:
“Study alert!
Patients with metastatic triple negative breast cancer planning to be treated with Sacituzumab Govitecan can enroll on the SIMONE study combining SG with nivolumab (PD-L1) or SG with nivolumab plus relatlimab (LAG3 inhibitor).”
NeoTRIPaPDL1 Transcriptomic Analysis Reveals Early Predictors of Response in TNBC
